New First-Line Option for Advanced ALK-Positive Lung Cancer

Published Date: 20 Dec 2024

In randomized study, ensartinib doubled PFS versus first-generation ALK inhibitor

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Alzheimer's Blood Test Gets FDA Clearance

2.

The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.

3.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

4.

New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy

5.

AI tool identifies women at high risk of interval breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot